LLYELI LILLY & Co

NYSE lilly.com


$ 941.03 $ 8.53 (0.91 %)    

Wednesday, 10-Jul-2024 15:59:56 EDT
QQQ $ 502.82 $ 2.94 (0.59 %)
DIA $ 397.18 $ 4.24 (1.08 %)
SPY $ 561.08 $ 5.26 (0.95 %)
TLT $ 92.64 $ 0.29 (0.31 %)
GLD $ 219.36 $ 0.80 (0.37 %)
$ 939.78
$ 936.98
$ 851.00 x 102
$ 0.00 x 0
$ 933.51 - $ 945.22
$ 431.12 - $ 935.00
2,419,859
na
842.79B
$ 0.57
$ 137.30
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eli-lilly-announces-cfo-change
Eli Lilly Announces CFO Change
07/10/2024 19:35:39

Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know.

Core News & Articles

The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating...

 only-25-patients-stick-with-novo-nordisks-wegovy-or-ozempic-after-2-years-a-study-shows-company-calls-data-insufficient

A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on t...

Core News & Articles

https://www.dailymail.co.uk/health/article-13620101/ozempic-quitting-patients-weight-loss-effects.html?ns_mchannel=rss&ns_c...

 eli-lillys-32b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attention-on-obesity-analyst

Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and ...

 sp-500-closes-at-record-high-ahead-of-inflation-data-fear--greed-index-remains-in-neutral-zone

The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record h...

 eli-lillys-mounjaro-outpaces-novo-nordisks-ozempic-in-weight-loss-effectiveness-study-shows

Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients o...

Core News & Articles

https://www.forbes.com/sites/roberthart/2024/07/08/zepbound-sheds-more-weight-than-wegovy-study-finds/Eli Lilly's popular o...

 eli-lillys-first-biotech-deal-of-2024-buys-chronic-disease-player-morphic-for-32b

Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic&#...

 whats-going-on-with-eli-lilly-shares-friday

Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.

 glp-1-treatments-such-as-wegvoy-mounjaro-cut-obesity-related-cancer-risks-study-finds

A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce th...

Core News & Articles

https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds